Comparative Pharmacology
Head-to-head clinical analysis: BYOOVIZ versus CIMERLI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BYOOVIZ versus CIMERLI.
BYOOVIZ vs CIMERLI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
BYOOVIZ (bevacizumab-maly) is a vascular endothelial growth factor (VEGF) inhibitor that binds to VEGF-A and prevents its interaction with receptors VEGFR-1 and VEGFR-2, thereby inhibiting angiogenesis and tumor growth.
CIMERLI (ranibizumab-eqrn) is a vascular endothelial growth factor (VEGF) inhibitor. It binds to VEGF-A isoforms (e.g., VEGF110, VEGF121, VEGF165) and prevents their interaction with receptors VEGFR-1 and VEGFR-2 on endothelial cells, thereby inhibiting angiogenesis and reducing vascular permeability.
0.5 mg (0.05 mL of 10 mg/mL solution) administered by intravitreal injection once every 4 weeks (monthly). Dose adjustment is not recommended.
0.5 mg (0.05 mL) administered by intravitreal injection once monthly (approximately every 28 days).
None Documented
None Documented
20 days (range 11–50 days) in patients; supports every-2- or 3-week dosing. Longer half-life in bevacizumab compared to other monoclonal antibodies due to FcRn-mediated recycling.
Terminal elimination half-life: 5.9 days (range 4.0–7.5 days) in patients with neovascular AMD after intravitreal administration. This supports monthly or bimonthly dosing intervals.
Bevacizumab (BYOOVIZ) is eliminated primarily via proteolytic catabolism, not renal or biliary excretion. No significant intact drug is excreted in urine or feces.
Primarily eliminated via intracellular catabolism; urinary excretion of intact drug is negligible (<0.1%). Biliary/fecal excretion of intact drug is minimal. No renal or hepatic metabolism in the classical sense.
Category C
Category C
VEGF Inhibitor
VEGF Inhibitor